Germany · Delayed Price · Currency is EUR Biofrontera AG Statistics
Total Valuation
Biofrontera AG has a market cap or net worth of EUR 18.72 million. The enterprise value is 13.24 million.
| Market Cap | 18.72M |
| Enterprise Value | 13.24M |
Important Dates
The last earnings date was Wednesday, September 30, 2026.
| Earnings Date | Sep 30, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Biofrontera AG has 6.08 million shares outstanding. The number of shares has decreased by -20.79% in one year.
| Current Share Class | 6.08M |
| Shares Outstanding | 6.08M |
| Shares Change (YoY) | -20.79% |
| Shares Change (QoQ) | -1.01% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 1.40M |
Valuation Ratios
The trailing PE ratio is 3.57.
| PE Ratio | 3.57 |
| Forward PE | n/a |
| PS Ratio | 1.19 |
| PB Ratio | 0.93 |
| P/TBV Ratio | 0.93 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 2.56 |
| EV / Sales | 0.84 |
| EV / EBITDA | 5.31 |
| EV / EBIT | 7.48 |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.60, with a Debt / Equity ratio of 0.08.
| Current Ratio | 3.60 |
| Quick Ratio | 2.74 |
| Debt / Equity | 0.08 |
| Debt / EBITDA | 0.64 |
| Debt / FCF | n/a |
| Interest Coverage | 180.20 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | 7.91% |
| Return on Capital Employed (ROCE) | 8.38% |
| Weighted Average Cost of Capital (WACC) | 1.85% |
| Revenue Per Employee | 257,500 |
| Profits Per Employee | 84,839 |
| Employee Count | 69 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Biofrontera AG has paid 605,000 in taxes.
| Income Tax | 605,000 |
| Effective Tax Rate | 37.93% |
Stock Price Statistics
The stock price has increased by +15.36% in the last 52 weeks. The beta is -0.41, so Biofrontera AG's price volatility has been lower than the market average.
| Beta (5Y) | -0.41 |
| 52-Week Price Change | +15.36% |
| 50-Day Moving Average | 2.85 |
| 200-Day Moving Average | 2.59 |
| Relative Strength Index (RSI) | 51.43 |
| Average Volume (20 Days) | 1,466 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Biofrontera AG had revenue of EUR 15.97 million and earned 5.26 million in profits. Earnings per share was 0.86.
| Revenue | 15.97M |
| Gross Profit | 12.94M |
| Operating Income | 1.80M |
| Pretax Income | 1.60M |
| Net Income | 5.26M |
| EBITDA | 2.09M |
| EBIT | 1.80M |
| Earnings Per Share (EPS) | 0.86 |
Balance Sheet
The company has 7.11 million in cash and 1.63 million in debt, with a net cash position of 5.48 million or 0.90 per share.
| Cash & Cash Equivalents | 7.11M |
| Total Debt | 1.63M |
| Net Cash | 5.48M |
| Net Cash Per Share | 0.90 |
| Equity (Book Value) | 20.41M |
| Book Value Per Share | 3.36 |
| Working Capital | 11.69M |
Cash Flow
| Operating Cash Flow | n/a |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 289,000 |
| Net Borrowing | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
Gross margin is 81.06%, with operating and profit margins of 11.29% and 32.95%.
| Gross Margin | 81.06% |
| Operating Margin | 11.29% |
| Pretax Margin | 9.99% |
| Profit Margin | 32.95% |
| EBITDA Margin | 13.10% |
| EBIT Margin | 11.29% |
| FCF Margin | n/a |
Dividends & Yields
Biofrontera AG does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | 20.79% |
| Shareholder Yield | 20.79% |
| Earnings Yield | 28.04% |
| FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on May 14, 2024. It was a reverse split with a ratio of 0.047619.
| Last Split Date | May 14, 2024 |
| Split Type | Reverse |
| Split Ratio | 0.047619 |
Scores
Biofrontera AG has an Altman Z-Score of -3.56 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -3.56 |
| Piotroski F-Score | 1 |